AlgaHealth

The Need

We might think twice about our everyday spending—but when it comes to our health and wellbeing, most people are far more likely to invest. Health and wellbeing expenses are valued, in fact, at hundreds of billions globally, with an ever-growing need for innovative solutions to age-old human problems, such as obesity.

Data shows that, in 2019, 60% of all adults in OECD countries were either overweight or obese, and could suffer related type-2 diabetes, cardiac and vascular failures, meaning a reduction in life expectancy by as much as 4 years. In addition to their reduced life expectancy, they are at high risk of developing severe illnesses such as cancer and dementia. Moreover, it was proven that overweight and obese children are 13% less likely to perform well at school and are less likely to complete higher education.

The Solution

Fucoxanthin is a healthy, highly effective ingredient that can be used to reduce health issues related to metabolic syndrome, such as being overweight or obese, diabetes, cardio-vascular diseases, and other conditions, but its current production processes make it extremely rare and difficult to manufacture at high quality and in large quantities, to meet the vast and growing demand.

AlgaHealth is a biotech company pioneering the development of smart, cost-effective applications of microalgae for the production of nutraceuticals. The company is developing a new source for fucoxanthin from its specially cultivated microalgae, and a new line of products that contain high quantities of it.

Technology

Microalgae in general contain much more fucoxanthin than seaweed, and AlgaHealth’s special strain of microalgae goes further to reach concentrations of up to 100 times more than the current seaweed source.

Additionally, since AlgaHealth’s microalgae are grown in a controlled environment, the product is available year-round and is of high quality and contaminant-free, as well as non-GMO. Growing the microalgae in a controlled, land-based facility and AlgaHealth’s proprietary “agro-manipulations” in its cultivation and production processes allow for easy upscaling and distributed production, which makes it far more sustainable than any current mass production solution.

The technology is based on unique, novel proprietary microalgae strains and innovative, patent-protected processes and solutions—to ensure a stable and sustainable production process, and remove this significant market bottleneck.

AlgaHealth has engaged with some of Israel's leading research institutes including The Hebrew University in Jerusalem, and The Volcani Institute — to conduct ground-breaking research and development projects that will put AlgaHealth years ahead of the competition: microalgae strain development to achieve 3x to 5x the current microalgae production rate, and AI-based real-time sensing, implementing machine learning as part of production control and optimization.

AlgaHealth’s products—NutriXanthin™ and its parallel for cosmetics, DermaXanthin™—are new products featuring an extremely high concentration of fucoxanthin and are best suited for use as ingredients of food supplements and cosmetics products. Moreover, they are unique in not requiring any organic solvents for their production.

DermaXanthin™ will be available to customers in Q4 2021 and NutriXanthin™ in Q1 2022, pending regulatory approval.

Among the innovative advantages of AlgaHealth’s tech:

AlgaHealth production process—a positive environmental impact on the ocean floor

Current production of fucoxanthin from macroalgae (seaweed) creates significant damage to the ocean floor, with very low efficiency in the process. In addition, the extraction of fucoxanthin from current sources, both macroalgae and microalgae, requires the use of organic solvents. AlgaHealth’s production processes are “green”, which significantly limits the negative environmental impact and prevents environmental damage, while increasing production substantially.